Compare AER & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AER | DGX |
|---|---|---|
| Founded | 1995 | 1967 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7B | 21.0B |
| IPO Year | 2006 | 1996 |
| Metric | AER | DGX |
|---|---|---|
| Price | $139.39 | $195.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $150.29 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 1.3M | 712.9K |
| Earning Date | 04-29-2026 | 04-21-2026 |
| Dividend Yield | 1.16% | ★ 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 2.24 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | N/A | $7.53 |
| Revenue Next Year | $1.44 | $3.77 |
| P/E Ratio | ★ $7.27 | $86.43 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $105.65 | $164.65 |
| 52 Week High | $154.94 | $213.50 |
| Indicator | AER | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 55.56 |
| Support Level | $131.59 | $192.76 |
| Resistance Level | $148.09 | $200.49 |
| Average True Range (ATR) | 3.60 | 3.90 |
| MACD | -0.67 | 0.75 |
| Stochastic Oscillator | 22.74 | 85.97 |
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.